» Articles » PMID: 23887097

Low-dose Methotrexate Results in the Selective Accumulation of Aminoimidazole Carboxamide Ribotide in an Erythroblastoid Cell Line

Overview
Specialty Pharmacology
Date 2013 Jul 27
PMID 23887097
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic and toxic response to low-dose methotrexate (MTX) in the treatment of autoimmune disease continues to be highly variable, resulting in a critical need to identify predictive biomarkers of response. Biomarker development has been hampered by an incomplete understanding of the molecular pharmacology of low-dose MTX. To address this issue, accumulation of the substrates for aminoimidazole carboxamide ribonucleotide transformylase (AICART) and thymidylate synthase (TS) was measured as markers of pharmacological activity of MTX in an erythroblastoid cell line. A 115-fold increase in the AICART substrate and anti-inflammatory mediator, 5-aminoimidazole-4-carboxamide-1-β-d-ribofuranosyl 5'-monophosphate (ZMP), was observed following exposure to 10 nM MTX but subsequently decreased with increasing MTX concentrations, declining to baseline levels with 1000 nM MTX. In contrast, the TS substrate, 2'-deoxyuridine 5'-monophosphate disodium salt (dUMP), displayed concentration-dependent accumulation, increasing 29-, 342-, and 471-fold over baseline with 10, 100, and 1000 nM MTX, respectively. Cellular levels of dUMP correlated with levels of the parent drug (MTX-PG1; r = 0.66, P < 0.001) and its polyglutamates (MTX-PG2-6) (r = 0.81, P < 0.001), whereas cellular levels of ZMP were only moderately correlated with MTX-PG1 (r = 0.34, P < 0.01). In contrast, accumulation of ZMP at 10 nM MTX was associated with a 2.9-fold increase in the AICART inhibitor dihydrofolate (DHF), represented primarily by long-chain DHF polyglutamates. Selectivity, defined as the ratio of ZMP to dUMP, was maximal following exposure to 6 nM MTX. Characterizing the range of MTX concentrations that selectively promote ZMP accumulation while preserving pyrimidine biosynthesis may lead to optimization of low-dose MTX therapy.

Citing Articles

Inactivation of cytidine triphosphate synthase 1 prevents fatal auto-immunity in mice.

Soudais C, Schaus R, Bachelet C, Minet N, Mouasni S, Garcin C Nat Commun. 2024; 15(1):1982.

PMID: 38438357 PMC: 10912214. DOI: 10.1038/s41467-024-45805-y.


A network-based approach to integrate nutrient microenvironment in the prediction of synthetic lethality in cancer metabolism.

Apaolaza I, Jose-Eneriz E, Valcarcel L, Agirre X, Prosper F, Planes F PLoS Comput Biol. 2022; 18(3):e1009395.

PMID: 35286311 PMC: 8947600. DOI: 10.1371/journal.pcbi.1009395.


Correlation between serum methotrexate-polyglutamate 3 (MTX-PG3) level and disease activity in rheumatoid arthritis patients: A prospective cohort study.

Musdalita E, Hidayat R, Sumariyono S, Wibowo S, Ariane A, Shatri H F1000Res. 2022; 11:187.

PMID: 35284067 PMC: 8891717. DOI: 10.12688/f1000research.108714.1.


Folic Acid Supplementation in Patients with Elevated Homocysteine Levels.

Kaye A, Jeha G, Pham A, Fuller M, Lerner Z, Sibley G Adv Ther. 2020; 37(10):4149-4164.

PMID: 32845472 PMC: 7497502. DOI: 10.1007/s12325-020-01474-z.


Metabolomic Profiling to Identify Molecular Biomarkers of Cellular Response to Methotrexate In Vitro.

Funk R, Singh R, Becker M Clin Transl Sci. 2019; 13(1):137-146.

PMID: 31651077 PMC: 6951846. DOI: 10.1111/cts.12694.


References
1.
Weinblatt M, Coblyn J, Fox D, Fraser P, HOLDSWORTH D, Glass D . Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med. 1985; 312(13):818-22. DOI: 10.1056/NEJM198503283121303. View

2.
Borsa J, Whitmore G . Studies relating to the mode of action of methotrexate. 3. Inhibition of thymidylate synthetase in tissue culture cells and in cell-free systems. Mol Pharmacol. 1969; 5(4):318-32. View

3.
Sant M, Lyons S, Phillips L, Christopherson R . Antifolates induce inhibition of amido phosphoribosyltransferase in leukemia cells. J Biol Chem. 1992; 267(16):11038-45. View

4.
Johnston A, Gudjonsson J, Sigmundsdottir H, Ludviksson B, Valdimarsson H . The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005; 114(2):154-63. DOI: 10.1016/j.clim.2004.09.001. View

5.
Baggott J, Morgan S, SAMS W, Linden J . Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis. Arch Dermatol. 1999; 135(7):813-7. DOI: 10.1001/archderm.135.7.813. View